Full Text View
Tabular View
No Study Results Posted
Related Studies
Etanercept for Wegener's Granulomatosis
This study has been completed.
Study NCT00005007   Information provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First Received: March 24, 2000   Last Updated: December 19, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Wegener's Granulomatosis
Additional conditions recognized in this trial
Wegener Granulomatosis
More general conditions related to this trial
Cardiovascular Diseases
Kidney Diseases
Lung Diseases
Lung Diseases, Interstitial
Respiratory Tract Diseases
Urologic Diseases
Vascular Diseases
Vasculitis
Interventions listed in this trial
Etanercept
Additional drug interventions recognized in this trial
TNFR-Fc fusion protein
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Gastrointestinal Agents
Immunologic Factors
Immunosuppressive Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
FDA Office of Orphan Products Development


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services